Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W7GU
|
|||
| Former ID |
DNC010978
|
|||
| Drug Name |
2,5-Dimethoxy-4'-amino-trans-stilbene
|
|||
| Synonyms |
BRN 2855929; 4-(2,5-Dimethoxy)stilbenamine; 4'-Stilbenamine, 2,5-dimethoxy-; 4-(2,5-Dimethoxyphenethyl)aniline; 2,5-Dimethoxy-4'-aminostilbene(trans); 4'-AMINO-2,5-DIMETHOXY STILBENE; CHEMBL1173699; 4-(2-(2,5-Dimethoxyphenyl)ethyl)benzenamine; Stilbenamine, 2',5'-dimethoxy-; 2',5'-Dimethoxy-4-stilbenamine; 23435-31-6; 4-[(E)-2-(2,5-Dimethoxyphenyl)ethenyl]aniline; 32180-65-7; 4-[2-(2,5-dimethoxyphenyl)vinyl]aniline; 4-[2-(2,5-dimethoxyphenyl)ethenyl]aniline; 2,5-Dimethoxy-4'-aminostilbene; 5803-51-0; DMBAS; AC1NTB1S
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H17NO2
|
|||
| Canonical SMILES |
COC1=CC(=C(C=C1)OC)C=CC2=CC=C(C=C2)N
|
|||
| InChI |
1S/C16H17NO2/c1-18-15-9-10-16(19-2)13(11-15)6-3-12-4-7-14(17)8-5-12/h3-11H,17H2,1-2H3/b6-3+
|
|||
| InChIKey |
OZGXSMOLBWHIQA-ZZXKWVIFSA-N
|
|||
| CAS Number |
CAS 23435-31-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Estradiol biosynthesis II | ||||
| Estradiol biosynthesis I | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | |||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Reactome | Endogenous sterols | |||
| WikiPathways | Metapathway biotransformation | |||
| Tryptophan metabolism | ||||
| Oxidation by Cytochrome P450 | ||||
| Ovarian Infertility Genes | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| FSH signaling pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.